These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

114 related articles for article (PubMed ID: 26757613)

  • 61. Efficacy and safety of ritonavir-boosted dual protease inhibitor therapy in antiretroviral-naive HIV-1-infected patients: the 2IP ANRS 127 study.
    Landman R; Capitant C; Descamps D; Chazallon C; Peytavin G; Katlama C; Pialoux G; Bentata M; Brun-Vézinet F; Aboulker JP; Yéni P;
    J Antimicrob Chemother; 2009 Jul; 64(1):118-25. PubMed ID: 19420019
    [TBL] [Abstract][Full Text] [Related]  

  • 62. Safety of etravirine in HIV-1/hepatitis B and/or C virus co-infected patients: pooled 96 week results from the Phase III DUET trials.
    Clotet B; Clumeck N; Katlama C; Nijs S; Witek J
    J Antimicrob Chemother; 2010 Nov; 65(11):2450-4. PubMed ID: 20801782
    [TBL] [Abstract][Full Text] [Related]  

  • 63. Phase 2 double-blind, randomized trial of etravirine versus efavirenz in treatment-naive patients: 48-week results.
    Gazzard B; Duvivier C; Zagler C; Castagna A; Hill A; van Delft Y; Marks S
    AIDS; 2011 Nov; 25(18):2249-58. PubMed ID: 21881478
    [TBL] [Abstract][Full Text] [Related]  

  • 64. Study of the impact of HIV genotypic drug resistance testing on therapy efficacy.
    Van Vaerenbergh K
    Verh K Acad Geneeskd Belg; 2001; 63(5):447-73. PubMed ID: 11813503
    [TBL] [Abstract][Full Text] [Related]  

  • 65. A randomized crossover study to compare efavirenz and etravirine treatment.
    Nguyen A; Calmy A; Delhumeau C; Mercier IK; Cavassini M; Fayet-Mello A; Elzi L; Genné D; Rauch A; Bernasconi E; Hirschel B;
    AIDS; 2011 Jan; 25(1):57-63. PubMed ID: 21076278
    [TBL] [Abstract][Full Text] [Related]  

  • 66. Antiretroviral treatment failure predicts mortality in rural Tanzania.
    Pettersen PS; Brox IK; Naman E; Bruun JN; Dyrhol-Riise AM; Trøseid M; Johannessen A
    Int J STD AIDS; 2015 Aug; 26(9):633-9. PubMed ID: 25122578
    [TBL] [Abstract][Full Text] [Related]  

  • 67. Simplification of protease inhibitor-containing regimens with efavirenz, nevirapine or abacavir: safety and efficacy outcomes.
    Chiesa E; Bini T; Adorni F; Capetti A; Rizzardini G; Faggion I; Mussini C; Sollima S; Melzi S; Bongiovanni M; Tordato F; Cicconi P; Castelnuovo B; Rusconi S; d'Arminio Monforte A
    Antivir Ther; 2003 Feb; 8(1):27-35. PubMed ID: 12713061
    [TBL] [Abstract][Full Text] [Related]  

  • 68. Outcomes of etravirine-based antiretroviral treatment in treatment-experienced children and adolescents living with HIV in Europe and Thailand.
    European Pregnancy And Paediatric Infections Cohort Collaboration Eppicc ; Lyons A; Thompson L; Chappell E; Ene L; Galli L; Goetghebuer T; Jourdain G; Noguera-Julian A; Kahlert CR; Königs C; Kosalaraksa P; Lumbiganon P; Marczyńska M; Marques L; Navarro M; Naver L; Okhonskaia L; Prata F; Puthanakit T; Ramos JT; Samarina A; Thorne C; Voronin E; Turkova A; Giaquinto C; Judd A; Collins IJ
    Antivir Ther; 2022 Jun; 27(3):13596535221092182. PubMed ID: 36029009
    [TBL] [Abstract][Full Text] [Related]  

  • 69. Etravirine plasma exposure is associated with virological efficacy in treatment-experienced HIV-positive patients.
    Calcagno A; Marinaro L; Nozza S; Aldieri C; Carbone A; Ghisetti V; Trentalange A; D'Avolio A; Castagna A; Di Perri G; Bonora S
    Antiviral Res; 2014 Aug; 108():44-7. PubMed ID: 24861522
    [TBL] [Abstract][Full Text] [Related]  

  • 70. Any impact of blips and low-level viraemia episodes among HIV-infected patients with sustained virological suppression on ART?
    Pernas B; Grandal M; Pertega S; Cañizares A; Castro-Iglesias Á; Mena Á; Rodriguez-Osorio I; Tabernilla A; Pedreira JD; Poveda E
    J Antimicrob Chemother; 2016 Apr; 71(4):1051-5. PubMed ID: 26702924
    [TBL] [Abstract][Full Text] [Related]  

  • 71. Archived HIV-1 DNA resistance mutations to rilpivirine and etravirine in successfully treated HIV-1-infected individuals pre-exposed to efavirenz or nevirapine.
    Gallien S; Charreau I; Nere ML; Mahjoub N; Simon F; de Castro N; Aboulker JP; Molina JM; Delaugerre C
    J Antimicrob Chemother; 2015 Feb; 70(2):562-5. PubMed ID: 25344807
    [TBL] [Abstract][Full Text] [Related]  

  • 72. Virological analysis of once-daily and twice-daily darunavir/ritonavir in the ODIN trial of treatment-experienced patients.
    Lathouwers E; De La Rosa G; Van de Casteele T; Baeten B; Tomaka F; De Meyer S; Picchio G
    Antivir Ther; 2013; 18(3):289-300. PubMed ID: 23558157
    [TBL] [Abstract][Full Text] [Related]  

  • 73. Pharmacokinetics and antiretroviral response to darunavir/ritonavir and etravirine combination in patients with high-level viral resistance.
    Boffito M; Winston A; Jackson A; Fletcher C; Pozniak A; Nelson M; Moyle G; Tolowinska I; Hoetelmans R; Miralles D; Gazzard B
    AIDS; 2007 Jul; 21(11):1449-55. PubMed ID: 17589191
    [TBL] [Abstract][Full Text] [Related]  

  • 74. Sensitive testing of plasma HIV-1 RNA and Sanger sequencing of cellular HIV-1 DNA for the detection of drug resistance prior to starting first-line antiretroviral therapy with etravirine or efavirenz.
    Geretti AM; Conibear T; Hill A; Johnson JA; Tambuyzer L; Thys K; Vingerhoets J; Van Delft Y;
    J Antimicrob Chemother; 2014 Apr; 69(4):1090-7. PubMed ID: 24284781
    [TBL] [Abstract][Full Text] [Related]  

  • 75. Triple nucleoside reverse transcriptase inhibitor- vs. nonnucleoside reverse transcriptase inhibitor-containing regimens as first-line therapy: efficacy and durability in a prospective cohort of French HIV-infected patients.
    Cuzin L; Pugliese P; Bugnon F; Delpierre C; Cua E; Billaud E; Massip P; Raffi F; Dellamonica P
    HIV Med; 2005 Nov; 6(6):388-95. PubMed ID: 16268820
    [TBL] [Abstract][Full Text] [Related]  

  • 76. Clinical and pharmacokinetic data support once-daily low-dose boosted saquinavir (1,200 milligrams saquinavir with 100 milligrams ritonavir) in treatment-naive or limited protease inhibitor-experienced human immunodeficiency virus-infected patients.
    Marin-Niebla A; Lopez-Cortes LF; Ruiz-Valderas R; Viciana P; Mata R; Gutierrez A; Pascual R; Rodriguez M
    Antimicrob Agents Chemother; 2007 Jun; 51(6):2035-42. PubMed ID: 17371813
    [TBL] [Abstract][Full Text] [Related]  

  • 77. Effectiveness and tolerance of single tablet versus once daily multiple tablet regimens as first-line antiretroviral therapy - Results from a large french multicenter cohort study.
    Cotte L; Ferry T; Pugliese P; Valantin MA; Allavena C; Cabié A; Poizot-Martin I; Rey D; Duvivier C; Cheret A; Dellamonica P; Pradat P; Parienti JJ;
    PLoS One; 2017; 12(2):e0170661. PubMed ID: 28152047
    [TBL] [Abstract][Full Text] [Related]  

  • 78. Week 96 outcomes of patients with less treatment experience versus more treatment experience receiving etravirine in the DUET trials.
    Anderson D; DeMasi R; DeLaitsch L; Surles T; Coate B
    Curr HIV Res; 2012 Apr; 10(3):256-61. PubMed ID: 22497697
    [TBL] [Abstract][Full Text] [Related]  

  • 79. Endothelial, inflammatory, coagulation, metabolic effects and safety of etravirine in HIV-uninfected volunteers.
    Gupta SK; Mi D; Liu Z; Saha C
    AIDS Patient Care STDS; 2011 Jun; 25(6):327-31. PubMed ID: 21470045
    [TBL] [Abstract][Full Text] [Related]  

  • 80. Efficacy and Safety of Doravirine-Based Regimens in Real Life: A Prospective Monocentric French Study.
    Garcia M; Martellosio JP; Giraud V; Béraud G; Catroux M; Roblot F; Le Moal G
    AIDS Res Hum Retroviruses; 2022 Oct; 38(10):779-781. PubMed ID: 36097760
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.